AdipoSeeds

AdipoSeeds, Inc., headquartered in Minato-ku, Tokyo, is a pioneering startup from Keio University specializing in regenerative medicine. The company focuses on developing and commercializing Platelet-Like Cells (PLC) derived from Adipose-derived Stem Cells (ASCL). These cells are sourced from subcutaneous fat tissue through liposuction, eliminating the need for complex and costly gene transfer processes. This innovative approach allows for the production of platelets in a safe, stable, and cost-effective manner, without the need for blood donations.

AdipoSeeds operates in the regenerative medicine market, serving clients in the medical and dental fields. The company's primary business model revolves around the development and commercialization of ASCL-derived PLCs as allogeneic regenerative medicine products. These products aim to obtain manufacturing and sales approval under the Pharmaceuticals and Medical Devices Law.

In addition to its core product development, AdipoSeeds has entered into a basic agreement with H.U. Cells, Inc. to explore a business alliance for Platelet-Rich Plasma (PRP) therapy. PRP therapy leverages the tissue-repairing capabilities of platelets, which are extracted from a patient's own blood and injected into the affected area. This therapy is supported by technical expertise from Keio University Hospital.

AdipoSeeds generates revenue through the development, manufacturing, and sales of its regenerative medicine products, as well as through contracted business services related to PRP therapy. The company aims to provide innovative, safe, and cost-effective solutions for conditions like thrombocytopenia and wound healing, making significant strides in the field of regenerative medicine.

Keywords: regenerative medicine, adipose-derived stem cells, platelet-like cells, thrombocytopenia, wound healing, PRP therapy, Keio University, H.U. Cells, cost-effective, gene transfer-free.